Compared to control non-targeting sgRNA, CRISPR-mediated inactivation of S100a8 in MDS cells restored erythropoiesis and restored a normal erythroid niche by interrupting the cycle of inflammation (Schneider et al., 2016). This evidence concerns the gene S100A8 and myelodysplastic syndrome.